Cefpiramide for injection

The main ingredient of this product is cefpiramide, and its chemical name is: (6R, 7R)-7-[(R)-2-(4-hydroxy-6-methyl-3-pyridinecarbonylamino)-2-(p-hydroxyphenyl)acetylamino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid.

This product is white or off-white crystalline powder.

It is mainly used clinically for pharyngitis, tonsillitis, acute and chronic bronchitis, pneumonia, suppurative lung diseases, pyelonephritis, cystitis, prostatitis, meningitis and gynecological infections caused by sensitive bacteria infections.

The common dosage for adults is 1-2g of cefpiramide per day, divided into 2 intravenous injections or intravenous drips. In case of refractory or severe infection, it can be increased to 4g per day according to different symptoms, divided into 2-3 intravenous drips. The common dosage for children is 30-80 mg per kilogram per day according to body weight, divided into 2-3 intravenous drips. In case of refractory or severe infection, it can be increased to 150 mg per kilogram per day according to different symptoms, divided into 2-3 intravenous drips. Dosage method and precautions: 1. When intravenously dripping this product, add glucose solution, electrolyte solution, amino acid solution and other infusions, and drip it after 30-60 minutes; 2. This drug can only be used for intravenous administration. Do not use injection water to dissolve the intravenous drip medication because the solution is not isotonic; 3. When large doses are administered intravenously, vascular irritation symptoms and thrombophlebitis may sometimes occur. In order to prevent such symptoms, attention should be paid to the dissolution of the injection solution, the selection of the injection site, the injection method, etc., and the injection speed should be as slow as possible; 4. It must be used quickly after dissolution, and if it needs to be stored, it must be used within 24 hours. 5. Cefpiramide should not be mixed with other drugs in the same container for intravenous use

According to literature reports, among the 15,442 cases of clinical studies conducted before and after the product was marketed, 617 cases (4%) had adverse reactions and abnormal laboratory tests, mainly rare digestive symptoms such as diarrhea and nausea, skin symptoms such as rash, blood abnormalities such as leukopenia and eosinophilia, renal function abnormalities such as increased BUN, creatine, and creatinine, and liver function abnormalities such as increased GOT and GPT. 1. Serious adverse reactions (1) Anaphylactic shock (<0.1%) Closely observe, discontinue the drug when symptoms occur, and take appropriate measures. (2) Severe renal dysfunction such as acute renal failure (<0.1%) Regularly check renal function, closely observe, and discontinue the drug when abnormalities are found, and take appropriate measures. (3) Severe colitis with bloody stools such as pseudomembranous colitis (<0.1%) Immediately discontinue the drug when abdominal pain, frequent diarrhea, and take appropriate measures. (4) Interstitial pneumonia, eosinophilic lung infiltration syndrome (<0.1%) If fever, cough, dyspnea, abnormal chest X-ray, eosinophilia, etc. occur, the drug should be discontinued, corticosteroids should be given, and appropriate treatment should be carried out. 2. Serious adverse reactions of similar drugs (1) Malignant bullous erythema multiforme (Stevens-Johnson syndrome), toxic epidermal necrosis syndrome (Lyell syndrome) It has been reported that malignant bullous erythema multiforme (Stevens-Johns syndrome) and toxic epidermal necrosis syndrome (Lyell syndrome) are occasionally seen when other cephalosporin antibiotics are used. Close observation should be made. If abnormalities occur, the drug should be discontinued and appropriate treatment should be carried out. (2) Hemolytic anemia It has been reported that hemolytic anemia occurs when other cephalosporin antibiotics (CET, CER, etc.) are used. If abnormalities are found, the drug should be discontinued and appropriate treatment should be carried out. 3. Other adverse reactions When the following adverse reactions occur, you should take adaptive measures such as reducing the dose and stopping the drug as needed. When such symptoms occur, you should stop the drug and take appropriate measures.

Patients with a history of anaphylactic shock caused by the ingredients of this drug should not use this drug; patients with a history of allergy to the ingredients of this drug or cephalosporin antibiotics are contraindicated.

Precautions for children: The safety of this drug for premature infants or newborns has not been established. Precautions for pregnancy and lactation: The safety of this drug for perinatal administration has not been established. Therefore, it can only be used for perinatal women or women who may become pregnant when the benefits of treatment outweigh the risks. Precautions for the elderly: When used in the elderly, the following issues should be noted: control the dosage and dosing interval, closely observe the patient's condition, and administer the drug with caution. (1) The physiological function of the elderly is reduced, and adverse reactions are more likely to occur. (2) The elderly sometimes have a tendency to bleed due to vitamin K deficiency.

1. Do not drink alcohol or alcoholic beverages. Taking them at the same time may cause facial flushing, nausea, tachycardia, sweating and headache. The mechanism is not clear yet, it may be the alcohol withdrawal symptoms caused by the N-methylthiotetrazolyl thiomethyl group connected to the 3rd position of the cephalosporin structure. 2. Taking anticoagulants at the same time may produce synergistic effects and cause bleeding. 3. Precautions when using at the same time

Keep away from light, sealed, and stored in a cool and dry place. Validity period: 24 months

0.5g (based on C25H24N8O7S2)

18 months

Jilin Huinan Changlong BLO-CHEMICAL Pharmaceutcal Co., Ltd.

• Founded in:

  1996-08-19

• Address:

  No. 31, Beishan Street, Chaoyang Town, Huinan County, Jilin Province

• Tax NO.:

  91220501243809189J

• Registered Funds:

  56.02 million yuan

• Website:

  Log in to view

• Email:

  Log in to view